Ragothaman Srinivasan - Spark Newswire

1 minute read

Anixa Initiates Patient Dosing in Initial-Stage Ovarian Cancer Study

Today, 11:35 PM

Anixa Biosciences (NASDAQ: ANIX) commenced treatment of the first patient in the clinical trial of its novel chimeric antigen receptor T-cell (CAR-T) therapy for ovarian cancer.

ANIX

1 minute read

Virios Therapeutics Commences Mid-Stage Long-COVID Study

By Ragothaman Srinivasan

Today, 11:35 PM

Virios Therapeutics (Nasdaq: VIRI) has initiated patient dosing in its exploratory Long-COVID trial evaluating IMC-2 (valacyclovir + celecoxib).

VIRI

2 minute read

Recap Of Friday’s Biotech Catalysts – End Of the Day Summary

By Ragothaman Srinivasan

Today, 11:35 PM

Pfizer (NYSE:PFE) announced positive top-line results from its pivotal U.S. Phase 3 study in infants evaluating its 20-valent…

ACER

1 minute read

Relief And Acer Therapeutics Secures Orphan Drug Designation From European Union For Metabolic Disorder Candidate

By Ragothaman Srinivasan

Today, 11:35 PM

The European Commission has granted orphan medicinal product designation in the EU to Relief Therapeutics and Acer Therapeutics’ (NASDAQ: ACER) lead asset ACER-001 (sodium phenylbutyrate) for the potential treatment of patients with Maple Syrup Urine Disease (MSUD).

ACER

1 minute read

Aptinyx Shares Plummet As Mid-Stage Fibromyalgia Study Missed Primary Endpoint

By Ragothaman Srinivasan

Today, 11:35 PM

Aptinyx Inc. (NASDAQ: APTX) announced results from a Phase 2b clinical study evaluating the effects of NYX-2925 in patients with fibromyalgia. The Phase 2b clinical study was designed to evaluate the efficacy and safety of NYX-2925 in approximately 300 patients with fibromyalgia.

APTX

3 minute read

Recap Of Thursday’s Biotech Catalysts – End Of the Day Summary

By Ragothaman Srinivasan

Today, 11:35 PM

The U.S. Food and Drug Administration (FDA) has accepted the Menarini Group and Radius Health’s (NASDAQ:RDUS), New Drug…

ALXO

1 minute read

AVITA Medical Shares Climb On Topline Results From Soft Tissue Reconstruction Study, Sees PMA Submission By Year-end

By Ragothaman Srinivasan

Today, 11:35 PM

AVITA Medical (NASDAQ: RCEL) announced topline results from its pivotal trial evaluating the safety and effectiveness of the RECELL System combined with meshed autograft for reduction of donor skin harvesting in soft tissue reconstruction.

RCEL

1 minute read

Passage Bio Commences Initial-Stage Brain Disorder Study

By Ragothaman Srinivasan

Today, 11:35 PM

Passage Bio (NASDAQ: PASG) has dosed the first patient in the global Phase 1/2 upliFT-D clinical trial evaluating PBFT02 for the treatment of patients with frontotemporal dementia (FTD) with granulin (GRN) mutations.

PASG

1 minute read

aTyr Pharma Shares Ascend As FDA Grants Fast Track Status To Lung Disease Candidate

By Ragothaman Srinivasan

Today, 11:35 PM

The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to aTyr Pharma’s (NASDAQ: LIFE) lead therapeutic candidate, efzofitimod (ATYR1923), for the treatment of pulmonary sarcoidosis, a major form of interstitial lung disease.

LIFE